What is Actio?
Headquartered in San Diego, Actio Biosciences is a clinical-stage biotechnology firm that integrates human genetics, data science, and small-molecule drug discovery to target the underlying biology of both rare and common diseases. The company's core competency lies in its ability to translate complex genetic insights into precision therapeutics. Its current pipeline is anchored by ABS-1230, a KCNT1 ion channel inhibitor designed for KCNT1-related epilepsy, and ABS-0871, a TRPV4 inhibitor currently under evaluation for Charcot-Marie-Tooth disease type 2C and overactive bladder. By focusing on specific molecular pathways, Actio aims to redefine treatment paradigms for patients with limited therapeutic options.
How much funding has Actio raised?
Actio has raised a total of $121M across 2 funding rounds:
Series A
$55M
Series B
$66M
Series A (2023): $55M with participation from Deerfield Management, EcoR1 Capital, and Canaan
Series B (2025): $66M led by Regeneron Ventures, Droia, Euclidean, Canaan, and Deerfield Management
Key Investors in Actio
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy, supporting companies across the ecosystem with flexible funding models.
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund focused on the biotech sector, dedicated to building long-term partnerships with entrepreneurs advancing therapeutic innovation.
Regeneron Ventures
Regeneron Ventures focuses on investing in innovative biotechnology and pharmaceutical companies to support the development of groundbreaking therapies and improve patient outcomes.
What's next for Actio?
With the successful closure of this major strategic investment, Actio is poised to transition into a more intensive phase of clinical development. The company will likely prioritize the expansion of its internal research capabilities and the acceleration of its lead programs through Phase 2 and Phase 3 trials. Strategic focus will remain on validating the efficacy of its small-molecule inhibitors while potentially exploring new therapeutic targets within its data-driven discovery platform. As the firm scales, the integration of additional clinical data will be paramount in establishing its long-term market viability and potential for future pharmaceutical partnerships or commercialization efforts.
See full Actio company page
